What drove PRFN.SW stock’s volume spike on 12 Mar 2026?

The volume spike likely reflects speculative trading and position adjustments ahead of possible corporate or clinical news. Volume reached 2,937,350 shares, about 3.42 times average, increasing short-term volatility.

What is Meyka AI’s view on PRFN.SW stock?

Meyka AI rates PRFN.SW **62.99/100 (Grade B, HOLD)** and projects a 12-month target of CHF0.0520 versus the current CHF0.0362, an implied upside of 43.65%. Forecasts are model-based and not guarantees.

What are the main risks for Kinarus Therapeutics (PRFN.SW)?

Principal risks include clinical trial setbacks, thin liquidity, and lack of immediate revenue. The stock trades below its 50-day and 200-day averages, increasing technical downside risk if catalysts fail to appear.

How should investors interpret PRFN.SW valuation metrics?

Valuation shows an EPS of -0.001 and a negative PE, reflecting a loss-making clinical-stage company. Enterprise value is modest and cash per share is minimal, so funding risk and dilution are key concerns.

CH Stocks

PRFN.SW Kinarus Therapeutics (SIX) -8.12% 12 Mar 2026: volume spike adds risk

ByDanny Kontos March 13, 2026March 13, 2026

PRFN.SW stock fell 8.12% and closed at CHF0.0362 on 12 Mar 2026 as trading volume jumped to 2,937,350 shares at market close on the SIX exchange in Switzerland. The move left the share price close to the 52-week low of CHF0.034 while the 50-day average price sits near CHF0.07. Investors pushed volume to roughly 3.42x the average, signalling heightened short-term interest and volatility in Kinarus Therapeutics Holding AG (PRFN.SW). This article examines the trading drivers, valuations, Meyka AI grade, and a model forecast to frame the most active session in context.